Myeloma Clinical Trials in Adelaide, South Australia

11 recruitingAdelaide, South Australia, Australia

Showing 111 of 11 trials

Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled138 locationsNCT06615479
Recruiting
Phase 1Phase 2

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals186 enrolled7 locationsNCT06669247
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 3

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Multiple Myeloma
Kite, A Gilead Company450 enrolled124 locationsNCT06413498
Recruiting
Phase 3

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma
Bristol-Myers Squibb1,216 enrolled285 locationsNCT05827016
Recruiting
Phase 3

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals410 enrolled159 locationsNCT05730036
Recruiting
Phase 1Phase 2

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Multiple Myeloma
AbbVie440 enrolled25 locationsNCT06892522
Recruiting
Phase 2Phase 3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

LeukemiaMyelomaNon Hodgkin's Lymphoma
Monash University900 enrolled3 locationsNCT07202078
Recruiting
Phase 2Phase 3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

LeukemiaMyelomaNon-Hodgkin's Lymphoma
Monash University900 enrolled3 locationsNCT07202052
Recruiting
Phase 2Phase 3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

LeukemiaMyelomaNon Hodgkin's Lymphoma
Monash University900 enrolled3 locationsNCT07202065
Recruiting
Phase 2Phase 3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

LeukemiaMyelomaNon Hodgkin's Lymphoma
Monash University900 enrolled3 locationsNCT07202091